Analysis of nanoparticle delivery to tumours
Analysis of nanoparticle delivery to tumours
复制标题
DOI：
10.1038/natrevmats.2016.14
复制
发表时间：
2016-05-01
影响因子：
83.5
通讯作者：
Chan, Warren C. W.
中科院分区：
文献类型：
--
作者：
Wilhelm, Stefan;Tavares, Anthony J.;Chan, Warren C. W.
将纳米颗粒靶向到恶性组织以改善诊断和治疗是一个流行的概念。然而，在调查了过去10年的文献后，发现只有0.7%（中位数）的纳米颗粒剂量被递送到实体肿瘤。这在纳米技术的制造、成本、毒性、成像和治疗效果等方面对人类使用的转化产生了负面影响。在本文中，我们对收集到的数据进行多元分析，揭示纳米粒子的理化参数、肿瘤模型和癌症类型对低递送效率的贡献。我们从肿瘤生物学（细胞间与细胞间转运，增强的渗透性和保留效应，以及物理化学依赖的纳米颗粒通过肿瘤基质转运）以及竞争器官（单核吞噬细胞和肾脏系统）的角度探讨了输送效率低的潜在原因，并提出了一项30年的研究策略来克服这一基本限制。解决纳米粒子的传递问题将加速纳米医学的临床转化。
Targeting nanoparticles to malignant tissues for improved diagnosis and therapy is a popular concept. However, after surveying the literature from the past 10 years, only 0.7% (median) of the administered nanoparticle dose is found to be delivered to a solid tumour. This has negative consequences on the translation of nanotechnology for human use with respect to manufacturing, cost, toxicity, and imaging and therapeutic efficacy. In this article, we conduct a multivariate analysis on the compiled data to reveal the contributions of nanoparticle physicochemical parameters, tumour models and cancer types on the low delivery efficiency. We explore the potential causes of the poor delivery efficiency from the perspectives of tumour biology (intercellular versus transcellular transport, enhanced permeability and retention effect, and physicochemical-dependent nanoparticle transport through the tumour stroma) as well as competing organs (mononuclear phagocytic and renal systems) and present a 30-year research strategy to overcome this fundamental limitation. Solving the nanoparticle delivery problem will accelerate the clinical translation of nanomedicine.